End Stage Renal Disease
Conditions
Brief summary
Objective: The purpose of this study is to demonstrate: -the non-inferiority of an experimental peritoneal dialysis solution compared to a current solution for the management of end stage renal disease (ESRD) in peritoneal dialysis patients.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients who have given written informed consent after the nature of the study has been explained. * Patients who are at least 18 years of age. * Patients who have been treated with CAPD using specific solutions for at least 60 days before the baseline visit.
Exclusion criteria
* Patients who have received antibiotics for the treatment of an episode of peritonitis within 30 days before the screening visit. - Patients who have had acute or chronic exit-site or tunnel infection in the past 14 days, counted from the last day of infection to the screening visit. * Patients who have other serious diseases, such as active, or if previously treated, residual malignancy or systemic infection. * Patients who have had a major illness or injury requiring hospitalisation within 30 days before the baseline visit. * Patients who have severe malnutrition (serum albumin \< 25 g/l by bromocresol green method). * Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted. * Patients who have received an investigational product within 30 days preceding the screening visit. * Patients who are pregnant or lactating. (NB: Female patients of childbearing potential must have a negative urine or serum pregnancy test at the time of the screening and will be required to use a medically acceptable means of contraception during their participation in this study). * Patients who have a significant psychiatric disorder or mental disability that could interfere with his/her ability to provide informed consent and/or comply with protocol procedures.
Countries
Canada